Investment Analysts’ Recent Ratings Updates for Glaukos (GKOS)

Several brokerages have updated their recommendations and price targets on shares of Glaukos (NYSE: GKOS) in the last few weeks:

• 8/1/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/30/2026 – Glaukos had its price target raised by HC Wainwright from $168.00 to $195.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by Stifel Nicolaus from $175.00 to $190.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by Citigroup Inc. from $175.00 to $188.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its “overweight” rating reaffirmed by Piper Sandler. They now have a $195.00 price target on the stock, up from $165.00.
• 7/30/2026 – Glaukos had its price target raised by Wells Fargo & Company from $138.00 to $178.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by Needham & Company LLC from $150.00 to $201.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by Truist Financial Corporation from $180.00 to $215.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by BTIG Research from $164.00 to $193.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Glaukos is now covered by UBS Group AG. They set a “neutral” rating and a $150.00 price target on the stock.
• 7/28/2026 – Glaukos is now covered by UBS Group AG. They set a “neutral” rating on the stock.
• 7/18/2026 – Glaukos was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/17/2026 – Glaukos had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/17/2026 – Glaukos had its price target raised by Stifel Nicolaus from $170.00 to $175.00. They now have a “buy” rating on the stock.
• 7/16/2026 – Glaukos had its price target raised by Truist Financial Corporation from $160.00 to $180.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Glaukos had its “buy” rating reaffirmed by BTIG Research. They now have a $164.00 price target on the stock.
• 7/8/2026 – Glaukos had its price target raised by Citigroup Inc. from $162.00 to $175.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Glaukos is now covered by HC Wainwright. They set a “buy” rating and a $168.00 price target on the stock.
• 7/6/2026 – Glaukos is now covered by HC Wainwright. They set a “buy” rating and a $168.00 price target on the stock.
• 7/4/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/1/2026 – Glaukos had its “overweight” rating reaffirmed by Piper Sandler. They now have a $165.00 price target on the stock.
• 6/21/2026 – Glaukos was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/17/2026 – Glaukos had its price target raised by Needham & Company LLC from $136.00 to $150.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In related news, CFO Alex R. Thurman sold 20,000 shares of Glaukos stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the sale, the chief financial officer owned 43,906 shares of the company’s stock, valued at approximately $7,908,787.78. This trade represents a 31.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 60,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 110,525 shares of company stock worth $19,125,006. Corporate insiders own 5.90% of the company’s stock.

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.